Zoetis Inc. (NYSE:ZTS) Receives $212.75 Consensus Target Price from Analysts

Zoetis Inc. (NYSE:ZTS) has been assigned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $212.75.

ZTS has been the topic of a number of research reports. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler increased their price target on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This trade represents a 9.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zoetis

Several large investors have recently modified their holdings of ZTS. JPMorgan Chase & Co. raised its stake in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after purchasing an additional 279,092 shares during the last quarter. Procyon Advisors LLC grew its position in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares during the period. Merit Financial Group LLC increased its stake in Zoetis by 19.4% in the 4th quarter. Merit Financial Group LLC now owns 7,502 shares of the company’s stock valued at $1,222,000 after purchasing an additional 1,219 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of Zoetis by 9.7% in the fourth quarter. Arkadios Wealth Advisors now owns 5,534 shares of the company’s stock valued at $902,000 after buying an additional 489 shares in the last quarter. Finally, Sanibel Captiva Trust Company Inc. acquired a new position in Zoetis during the fourth quarter worth about $232,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of ZTS opened at $161.33 on Monday. The company has a 50 day moving average price of $156.58 and a 200-day moving average price of $165.05. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market capitalization of $71.82 billion, a PE ratio of 29.49, a PEG ratio of 2.78 and a beta of 0.94. Zoetis has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the previous year, the business earned $1.38 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Equities analysts predict that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.